Non-invasive prediction of significant hepatic fibrosis in individuals with chronic hepatitis C infection using fibrosis risk score and machine learning models

Table 2 Comparison of baseline characteristics and biochemical parameters between the training and validation cohorts, n (%)

Parameters	Training dataset (n = 214)	Validation dataset (n = 102)	P value
Group			0.815
F0-F1	106 (49.5)	49 (48)
F2	36 (16.8)	21 (20.5)
F3	38 (17.8)	18 (17.6)
F4	34 (15.9)	14 (13.7)
Gender			0.994
Males	109 (50.9)	52 (51)
Females	105 (49.1)	50 (49)
Age (years)	46.88 ± 13.5	47.12 ± 11.6	0.871
Body mass index	23.86 ± 3.44	24.01 ± 3.39	0.715
Diabetes			0.70
Yes	30 (14)	16 (15.6)
No	184 (86)	86 (84.3)
Platelet count (× 109/L)	145.44 ± 30.83	144.1 ± 29.2	0.708
Bilirubin (mg/dL)	0.75 ± 0.26	0.756 ± 0.27	0.852
AST (U/L)	36 (25, 60)	40 (25, 63)	0.55
ALT (U/L)	42 (23, 47)	39 (25, 51)	0.66
GGT (U/L)	34 (21, 55)	36 (20, 53)	0.90
ALP (U/L)	59 (48, 77)	63.7 (54, 80)	0.07
Serum albumin (g/dL)	3.53 ± 0.26	3.57 ± 0.33	0.284
Total protein (g/dL)	7.02 ± 1.21	7.01 ± 1.13	0.943
Total cholesterol (mg/dL)	148.33 ± 19.12	146.6 ± 22.61	0.505
Triglycerides (mg/dL)	128 (111, 167)	133.2 (112, 174)	0.38
HDL (mg/dL)	35 (27, 43)	31.9 (25, 48)	0.98
LDL (mg/dL)	80.11 ± 14.3	78.33 ± 15.2	0.323
VLDL (mg/dL)	24.32 ± 11.16	23.89 ± 17.68	0.822

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: γ-glutamyl transferase; ALP: Alkaline phosphatase; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; VLDL: Very low-density lipoprotein.